National Institutes of Health (NIH)

The trial will enroll approximately 30,000 adult volunteers at 80 sites in the United States to evaluate if the candidate vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19).

New laboratory and point-of-care tests to enable access and rapid result.

NIH observational study suggests that the drug may decrease risk of pneumonia and death in this population.

The trend could threaten decades of public health work against heart disease.

Experimental treatment to modify the skin microbiome may offer long-term benefits.

The trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings.

NIH research finds higher risk and worse outcomes for those with addiction.

HABLE study prioritizes brain imaging and biomarker research among Mexican Americans.

Effort is part of the Accelerating Medicines Partnership to promote development of effective, targeted treatments.

Pages